GLP-1 Peptide Atlas, by Delfa

GLP-1 AtlasGLP-1 Peptide Atlas

← Trials/Trial dossier/NCT06927401

Not yet recruitingPhase NA

Evaluate the Detection of Retained Gastric Contents and Assess Safety Using the Flower Capsule Endoscopy in Healthy Individuals and GLP-1 Receptor Agonist Users

Lead sponsor

Asian Institute of Gastroenterology, India

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

—

Enrollment

36

estimated

Study population

Healthy volunteers, Perioperative / gastric aspiration risk

Key I/E criterion

—

Primary endpoint

•Detection of Retained Gastric Contents

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06927401

Org study IDETX-IND-01

Timeline

Milestones

Study start2025-04-08estimated

Study first posted2025-04-15actual

Last update posted2025-04-15actual

Primary completion2025-06-30estimated

Study completion2025-08-30estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Healthy volunteersPerioperative / gastric aspiration risk

Eligibility

Who can enroll

Minimum age18 Years

Maximum age65 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

1. Age > 18 years and < 65 years (male or female)

2. Willing and able to sign an IEC-approved informed consent form

3. Willing and able to comply with all study requirements

Exclusion criteria

1. History of gastrointestinal disorders

2. History of gastroparesis

3. History of prior gastric surgery

4. Swallowing disorders

5. Contraindications to EGD or capsule endoscopy

6. Use of GLP-1 receptor agonists in the last 3 months

7. Diagnosed with diabetes mellitus

8. Classified as obese (based on BMI criteria)

9. Pregnant or lactating

Endpoints (9)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

6

Patient-reported / QoL

1

Safety / tolerability / PK

1

Other (unclassified)

1

Patient-reported / QoL

1 endpoint

Secondary/protocol endpoint

Patient Tolerance Score for Flower Capsule

Time frame:Immediately after Flower capsule examination

descriptive

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Adverse Events Related to Flower Capsule

Time frame:From Day 0 to Day 14

Treatment-emergent AEs (any)

event count, event

componentsNausea

Other clinical outcomes

6 endpoints

Primary/protocol endpoint

Detection of Retained Gastric Contents Using Flower Capsule

Time frame:Within 1 hour post-capsule ingestion

threshold achievement, descriptive

Secondary/protocol endpoint

Visualization of Gastric Anatomical Landmarks

Time frame:Within 1 hour post-capsule ingestion

descriptive

Secondary/protocol endpoint

Gastric Mucosal Visualization Score

Time frame:Within 1 hour post-capsule ingestion

descriptive

Secondary/protocol endpoint

Gastric Cleanliness Score

Time frame:Within 1 hour post-capsule ingestion

descriptive

Secondary/protocol endpoint

Time to Complete Gastric Examination

Time frame:Within 1 hour post-capsule ingestion

descriptive

Secondary/protocol endpoint

Capsule Swallowing Success

Time frame:Within 15 minutes of capsule administration

descriptive

Other (unclassified)

1 endpoint

Secondary/protocol endpoint/low confidence

Total Water Volume Consumed

Time frame:Prior to capsule ingestion

descriptive

Publications (7)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Glucagon-Like Peptide Receptor-1 Agonists Used for Medically-Supervised Weight Loss in Patients With Hip and Knee Osteoarthritis: Critical Considerations for the Arthroplasty Surgeon.
Arthroplasty today2024 Jun (month)PMID39071832doi:10.1016/j.artd.2024.101327via CT.gov background
Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy.
Journal of clinical anesthesia2023 Aug (month)PMID36870274doi:10.1016/j.jclinane.2023.111091via CT.gov background
Assessment of residual gastric volume using point-of-care ultrasonography in adult patients who underwent elective surgery.
The ultrasound journal2023 Feb 8PMID36752856doi:10.1186/s13089-023-00307-8via CT.gov background
Ultrasound-guided estimation of gastric residual volume using Perlas's formula: A validation study in patients.
Indian journal of anaesthesia2022 Apr (month)PMID35663207doi:10.4103/ija.ija_783_21via CT.gov background
Pulmonary Aspiration of Gastric Contents: A Closed Claims Analysis.
Anesthesiology2021 Aug 1PMID34019629doi:10.1097/ALN.0000000000003831via CT.gov background
Preoperative assessment of gastric contents and volume using bedside ultrasound in adult patients: A prospective, observational, correlation study.
Indian journal of anaesthesia2018 Oct (month)PMID30443057doi:10.4103/ija.IJA_147_18via CT.gov background
Pneumonitis and pneumonia after aspiration.
Journal of dental anesthesia and pain medicine2017 Mar (month)PMID28879323doi:10.17245/jdapm.2017.17.1.1via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.